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DOI 10.1016/j.ccr.2011.10.016SUMMARYAngiogenesis is regulated by the balance of proangiogenic VEGF165 and antiangiogenic VEGF165b splice
isoforms. Mutations in WT1, the Wilms’ tumor suppressor gene, suppress VEGF165b and cause abnormal
gonadogenesis, renal failure, and Wilms’ tumors. In WT1 mutant cells, reduced VEGF165b was due to lack
of WT1-mediated transcriptional repression of the splicing-factor kinase SRPK1. WT1 bound to the SRPK1
promoter, and repressed expression through a specific WT1 binding site. InWT1mutant cells SRPK1-medi-
ated hyperphosphorylation of the oncogenic RNA binding protein SRSF1 regulated splicing of VEGF and
rendered WT1 mutant cells proangiogenic. Altered VEGF splicing was reversed by wild-type WT1, knock-
down of SRSF1, or SRPK1 and inhibition of SRPK1, which prevented in vitro and in vivo angiogenesis and
associated tumor growth.INTRODUCTION
Tumor growth requires new vessel formation, and this is driven
predominantly by VEGF, the most potent angiogenic molecule
known and the principal target for antiangiogenic therapy
(Hurwitz et al., 2004). VEGF is alternatively spliced to form two
families, one by splicing to a proximal 30 splice site in exon 8
(Houck et al., 1991), and a second by splicing to a distal 30 splice
site in exon 8 (Bates et al., 2002; Ce´be Suarez et al., 2006;Significance
Regulation of angiogenesis is critical for tumor growth. This is
genic isoforms, formed by alternative splicing, are found in nor
Here, we identify a link between mutations in a tumor suppres
transcriptional regulation of a splicing-factor kinase indicat
SRPK1, (2) SRPK1 may be a target for antiangiogenic therapy
as environmental control can regulate tumor growth. These re
be altered in cancer—angiogenesis and alternative splicing.
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selection results in angiogenic isoforms of VEGF, including
VEGF165, distal splice-site (DSS) selection results in a family
with antiangiogenic properties (e.g., VEGF165b; see Figure S1A
available online). VEGF165b inhibits VEGFR2 signaling by
inducing differential phosphorylation (Kawamura et al., 2008)
and intracellular trafficking (Ballmer-Hofer et al., 2011), and it
blocks angiogenesis in vivo in the mouse dorsal skin and chick
chorioallantoic membrane (Ce´be Suarez et al., 2006), rabbitregulated by the proangiogenic VEGF isoforms. Antiangio-
mal, healthy tissues and are downregulated in many tumors.
sor gene and regulators of angiogenesis. This link, through
es that (1) WT1 regulates splicing through repression of
, and (3) alternative splicing in tumors under genetic as well
sults provide a pathway linking two mechanisms known to
.
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WT1 Regulates VEGF Splicing by SRPK1 Suppressioncornea and rat mesentery (Woolard et al., 2004), developing rat
ovary (Artac et al., 2009) and testis (Baltes-Breitwisch et al.,
2010), melanoma, prostate, renal, and colon cancer (Varey
et al., 2008), sarcoma, and metastatic melanoma(Rennel et al.,
2008), and in the mouse retina and choroid (Hua et al., 2010;
Konopatskaya et al., 2006). The second member of the family
so far investigated, VEGF121b is also antiangiogenic in the
retina and in colon cancer (Rennel et al., 2009). The role of the
antiangiogenic family has not yet been investigated in as much
detail as the angiogenic family, although it appears to be
relatively highly expressed in nonangiogenic tissues (Woolard
et al., 2009) and is downregulated during angiogenesis (Bates
et al., 2002; Perrin et al., 2005; Varey et al., 2008). VEGF165b is
downregulated in the mammary gland during pregnancy, when
vascular remodelling and angiogenesis are required for epithelial
gland formation. Overexpression of VEGF165b in the mammary
gland during pregnancy inhibits duct formation, resulting in
reduced milk formation and pup starvation (Qiu et al., 2008),
and inhibition of endogenous VEGF165b in the ovary results in
abnormal angiogenesis and increased follicle progression
(Artac et al., 2009). In the kidney, expression of VEGF165b in
the podocyte controls permeability in the kidney and maintains
normal glomerular filtration rates by regulating fenestral forma-
tion (Qiu et al., 2010).
As VEGF165b and VEGF165 are generated from the same tran-
script, the relative amount of the proangiogenic versus antian-
giogenic isoforms is dependent upon splicing to either the PSS
(angiogenic VEGF165) or the DSS (antiangiogenic VEGF165b)
(Harper and Bates, 2008). The control of this splicing is poorly
understood, but recent studies have identified the role of three
key serine-arginine-rich (SR) proteins, SRSF6 (SRp55) (Manetti
et al., 2011; Nowak et al., 2008), SRSF1 (ASF/SF2) (Nowak
et al., 2010), and SRSF2 (SC35) (Merdzhanova et al., 2010), in
the control of the terminal splice-site selection. SRSF1 has
been implicated in proximal splice-site selection, induced by
IGF-1, and binding to the region around the PSS. SRSF6 has
been implicated in distal splice-site selection as it binds around
the DSS and is upregulated by TGFb1 in systemic sclerosis,
resulting in increased VEGF165b expression and inhibition of
angiogenesis (Manetti et al., 2011). A key study by Schumacher
et al. in 2007 identified a lack of the antiangiogenic isoform in
laser-dissected glomeruli of Denys Drash Syndrome (DDS)
patients with a genetic mutation in the Wilms’ tumor suppressor
gene WT1 (Schumacher et al., 2007). These patients have
increased risk of Wilms’ tumors, intersex disorders, and renal
failure (Denys et al., 1967; Drash et al., 1970). Wilms’ tumors
are highly vascularized tumors with high VEGF levels (Blann
et al., 2001; Sko¨ldenberg et al., 2001), and WT1 mutations or
altered expression are also found in other highly vascularized
tumors such as prostate cancer, hematological cancers, and
colorectal, breast, desmoid and brain tumors (Hohenstein and
Hastie, 2006). WT1 is also expressed as different isoforms by
alternative splicing (Haber et al., 1991). The most widely studied
isoforms are the inclusion or exclusion of exon 5 and an alterna-
tive splice donor site in exon 9, which encodes three amino
acids, KTS. The -KTS isoforms interact preferentially with DNA.
Thus, WT1 can be exon 5+ or exon 5 and KTS+ or KTS,
and all four isoforms are expressed in several tissues (Morrison
et al., 2008). As DDS-causing mutations in WT1 can alter VEGFCansplicing (Schumacher et al., 2007), we have investigated this
link between WT1 and splicing of the VEGF transcript, testing
the hypothesis that WT1 mutations regulate splicing through
splice-factor-specific mechanisms.
RESULTS
DDS Cells Have Reduced Distal Splice-Site Selection
in VEGF Resulting in Less VEGF165b
Schumacher et al. have shown that laser-dissected glomeruli
from patients with DDS lack VEGF165b (Schumacher et al.,
2007). To determine whether this was reproduced in an in vitro
cell system, we used the previously described conditionally
immortalized cell line from a patient with a C1096T mutation in
WT1 (Viney et al., 2007). This results in a single amino acid
substitution at amino acid 366 from an arginine to a cysteine in
the third zinc finger, critical for DNA binding. Figure 1A shows
that whereas normal podocytes express both isoforms approxi-
mately equally, in the DDS podocytes the VEGF165 isoform was
dominant. To ensure that this was due to a lack of a functional
WT1 gene, a stable DDS cell line was generated expressing
wild-type WT1 (+exon5/KTS; ‘‘rescued’’ DDS). This restored
expression of VEGF165b. To determine whether altered splicing
resulted in altered VEGF165b protein levels, cells were lysed,
protein extracted, and subjected to VEGF ELISA, using a
pan-VEGF capture antibody and then either a pan-VEGF or a
VEGF165b specific detection antibody. Figure 1B shows that
DDS cells had increased VEGF165, but decreased VEGF165b.
Rescued DDS cells restored overall VEGF expression and
splicing toward normal podocyte levels. Quantitative PCR
(qPCR) indicated no change in total VEGFmRNA levels between
DDS (0.10 ± 0.01% of GAPDH) and wild-type (0.15 ± 0.06% of
GAPDH) cell lines, and overexpression of wild-type WT1 (+/)
also resulted in no change in total VEGF expression (0.13 ±
0.01%). To confirm that this was VEGF165b and VEGF165 being
expressed, proteins were subjected to immunoblot. Figure 1C
shows that it was the 165 amino acid isoform (VEGF165b) that
was altered. To determine whether podocytes from DDS
patients with other mutations inWT1 also had altered VEGF165b
expression, conditionally immortalized podocytes generated
from patients with M342R or G349C mutations were used. Fig-
ure 1D shows that cells derived from both additional patients
had reduced VEGF165b expression relative to normal podocytes.
To determine whether WT1 was capable of altering expression
in other cell types, HeLa cells (which normally express low
levels of VEGF165b) and HEK293T cells (which do express
VEGF165b) were examined. Figure 1E shows that transfection
of HeLa cells with either WT1/ (exon5/KTS) or WT1+/
(+exon5/KTS) resulted in VEGF165b expression and reduced
VEGF165 expression, and in HEK293 cells this transfection
resulted in increased VEGF165b and reduced VEGF165. The pres-
ence or absence of WT1’s exon 5 did not alter the effect, but
the +KTS isoforms (WT1/+ and WT1+/+) were unable to switch
splicing to increase VEGF165b expression in either HeLa (Fig-
ure S1B) or HEK cells (Figure S1C). Splice-site selection in
exon 9 (+KTS) of WT1 itself was not altered in DDS cells (Fig-
ure S1D). Thus, to our surprise, the splicing effect is limited to
isoforms that lack the KTS sequence, isoforms that are mostly
associated with stable DNA binding of its GC rich targetcer Cell 20, 768–780, December 13, 2011 ª2011 Elsevier Inc. 769
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Figure 1. Wild-Type WT1 Induces Antiangiogenic VEGF165b Expression
(A) RT-PCR of mRNA extracted from normal or DDS podocytes using primers that detect both proximal and distal splice isoforms of VEGF. VEGF165 and
VEGF165b cDNAs are used as positive controls. Transfection of DDS podocytes with WT1 (+exon 5/KTS) restored VEGF165b splicing. Boxes indicate exon
usage represented by the bands.
(B) ELISAs for VEGF165b or VEGF165 protein using a pan-VEGF capture antibody and specific detection antibodies. VEGF165 was calculated from the difference
between pan-VEGF and VEGF165b.
(C) Immunoblot of protein extracted from normal podocytes, DDS podocytes, or DDS cells transfected with wild-type WT1(+/) using antibodies to VEGF165b,
total VEGF or GAPDH.
(D) RT-PCR of podocyte cell lines (three replicates) from three different DDS patients with different WT1 mutations show reduced VEGF165b expression.
(E) RT-PCR of mRNA from HeLa and HEK293 cells show expression of VEGF165b in HEK293 but not HeLa cells (untr = untransfected), but both cell types have
increased VEGF165b expression in the presence of WT1 (/), and WT1 (+/).
(F) Transfection of HEK293 cells with plasmids containing DDS-causing WT1 mutations abolished VEGF165b expression. Wild-type WT1(+/) overexpression
increases distal splicing relative to proximally spliced isoforms. Bar charts are mean ± SEM. See also Figure S1.
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WT1 Regulates VEGF Splicing by SRPK1 Suppressionsequence, suggesting it was not a direct RNA binding effect of
WT1 but due to a transcriptional target of WT1. To determine
whether other DDS mutations could alter splicing in HEK cells,770 Cancer Cell 20, 768–780, December 13, 2011 ª2011 Elsevier Incwe transfected HEK cells with WT1 containing the R366C,
M342R, or R394W DDS mutations and a C-terminal deletion
(Bor et al., 2006). All four mutations reduced VEGF165b.
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WT1 Regulates VEGF Splicing by SRPK1 Suppressionexpression relative to untransfected cells, whereas wild-type
WT1(+/) transfection increased the ratio of VEGF165b to
VEGF165 (Figure 1F).
The Splice Factor SRSF1 Is Nuclear in DDS Podocytes
and Regulates VEGF Splicing
Wehave previously shown that overexpression of splicing factor,
arginine/serine-rich 1 (SRSF1, also called SFRS1, ASF, SF2,
SF2/ASF, or ASF/SF2) results in increased VEGF165 but not
VEGF165b (Nowak et al., 2008). To determine whether there
was any alteration in SRSF1 expression, podocytes were stained
with a goat polyclonal anti-SRSF1 antibody. In normal podo-
cytes, SRSF1 was found in both the nucleus and the cytoplasm
whereas in DDS cells it was localized predominantly in the
nucleus. In rescued DDS cells, cytoplasmic localization of
SRSF1 was restored (Figure 2A). To confirm this, cells were
stained with a different mouse monoclonal SRSF1 antibody
and similar staining was seen (Figure S2A). Staining of HeLa cells
(no VEGF165b expression) indicated nuclear staining of SRSF1,
but HEK293 cells (VEGF165b and VEGF165 expression) showed
both nuclear and cytoplasmic staining (Figure S2B), consistent
with nuclear localization of SRSF1 predicting reduced VEGF165b
expression. To examine relative nuclear localization, a nuclear
extract or whole-cell lysate from normal or DDS podocytes
was subjected to immunoblotting with an anti-SRSF1 antibody.
Figure 2B shows that whereas total SRSF1 protein expression
(whole-cell lysate) is the same in DDS and normal podocytes, it
is weakly localized in the nucleus in normal cells (intensity was
18 ± 6% of whole-cell lysate intensity) but strongly localized in
the nucleus of DDS cells (95 ± 5%, N = 3). qPCR was carried
out to confirm that there was no overall change in SRSF1 expres-
sion, which was not significantly different in DDS podocytes
(0.12 ± 0.02% of GAPDH) compared with wild-type (0.23 ±
0.12%) or rescued (0.12 ± 0.01%) cells. SRSF1 is known to
shuttle to the nucleus when phosphorylated (Sanford et al.,
2005, 2008). To explore whether nuclear SRSF1 was phosphor-
ylated in DDS podocytes, a high-resolution immunoblot of
nuclear or cytoplasmic protein, untreated or treated with phos-
phatase, was carried out using two different SRSF1 antibodies.
Figure 2C shows that whereas cytoplasmic SRSF1 was unaf-
fected by phosphatase treatment, nuclear lysate treatment
with phosphatase resulted in a lower-molecular-weight band.
To then determine the phosphorylation status of SRSF1 after
WT1 mutation, we immunoprecipitated protein from whole-cell
lysate with an anti-SRSF1 antibody, then probed with a pan-
phospho-SR protein antibody. Compared with normal podo-
cytes (77 ± 2.5% of SRSF1 intensity) there was stronger
phosphorylation of SRSF1 in DDS podocytes (87 ± 1.6%), and
this was inhibited in the rescued DDS cells (71 ± 1%; Figure 2D).
This was also seen when protein was immunoprecipitated with
a phospho-SR protein and probed for SRSF1 (Normal 181 ±
7% of SRSF, DDS 244 ± 13%, rescued 163 ± 11%; Figure 2E).
To determine whether nuclear SRSF1 was required for the inhi-
bition of VEGF distal splicing a vector encoding nuclear-targeted
SRSF1 (that fails to shuttle to the cytoplasm) was transfected
into the podocytes. This resulted in complete inhibition of distal
VEGF splicing (Figure 2F).
To determine whether SRSF1 was exhibiting greater splicing
activity in DDS than normal podocytes, known targets ofCanSRSF1 were investigated. Mitogen-activated protein kinase
signal-integrating kinase 2 (MNK2) is expressed as two splice
isoforms, and SRSF1 overexpression has been shown to
increase splicing of the MNK2b isoform (Karni et al., 2007).
hnRNPA2/B1 is also alternatively spliced by SRSF1, with
increased SRSF1 activity favoring inclusion of exon 2 to
result in hnRNPB1 expression. MNK2 and hnRNPA2/B1 mRNA
expression were investigated by RT-PCR. Figure 2G shows
that DDS podocytes expressed the MNK2b isoform, whereas
normal podocytes express MNK2a. The expression of MNK2b
in rescued DDS cells once again reflected its splicing pattern in
wild-type cells. Similarly, in DDS podocytes, hnRNPB1 was
increased, and this was restored by rescue withWT1. In contrast
Rac1b, another SRSF1 identified target (Gonc¸alves et al., 2009)
was not altered in DDS (Figure S2C).
To determine whether SRSF1 was required for preferential
proximal splicing of VEGF, DDS podocytes were transfected
with three different siRNAs to SRSF1. qPCR for SRSF1 showed
that this resulted in a reduction to 8.5 ± 4%, 15 ± 9.3%, and
15.8 ± 8.8%of SRSF1mRNA expression in the scrambled siRNA
transfected cells for siRNA1, 2, and 3, respectively. Figure 2H
shows that all three siRNAs resulted in VEGF165b expression.
To ensure that this was not an off-target effect, cells were
transfected with an SRSF1 construct resistant to siRNA1.
This abolished the effect of siRNA1, again inhibiting VEGF165b
expression (Figure S2D). Overexpression of splice factors
SRSF1, 2, 4–7 had minimal effect on VEGF165b expression in
HeLa cell, and overexpression of SRSF1–6 and SAM68 had no
effect on DDS cells (Figure S2E).
SRPK1Expression Is Elevated inDenysDrash Syndrome
SRSF1 nuclear localization is brought about by phosphorylation
by a number of splicing factors, including SRPK1 (Zhong
et al., 2009). To investigate whether SRPK1 might be involved,
we measured SRPK1 mRNA levels in podocytes by qPCR.
DDS podocytes showed a 15-fold increase in SRPK1 mRNA
compared with normal podocytes (Figure 3A). This increase
was significantly reduced in rescued DDS cells (p < 0.01,
ANOVA). To identify whether SRPK1 protein levels were also
altered, we subjected protein extracts from podocytes to immu-
noblotting using an SRPK1 antibody. Figure 3B shows that
SRPK1 protein expression was increased in DDS cells (89 ±
23% of GAPDH) compared with normal podocytes (68 ± 22%),
but not in rescued DDS cells (79 ± 23%). To determine whether
SRPK1 activation could be affecting SRSF1 localization, we
used a small molecule inhibitor of SRPK1, N-[2-(1-piperidinyl)-
5-(trifluoromethyl)phenyl] isonicotinamide (SRPIN340) (Fukuhara
et al., 2006). Treatment of DDS cells with 10 mM SRPIN340
or siRNA to SRPK1 resulted in relocalization of the SRSF1 to
the cytoplasm (Figure 3C), as measured using a polyclonal
goat antibody to SRSF1. This was confirmed with a monoclonal
antibody to SRSF1 (Figure S3A).
SR Protein Kinase Inhibition Restores the Expression
of Antiangiogenic VEGF
To identify whether SRPIN340 could affect alternative splicing
of VEGF, cells were treated with 10 mM SRPIN340 and mRNA
extracted and subjected to RT-PCR. Figure 3D shows that
normal podocytes treated with SRPIN340 increased theircer Cell 20, 768–780, December 13, 2011 ª2011 Elsevier Inc. 771
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Figure 2. Mutant WT1 Induces Phosphorylation and Nuclear Localization of SRSF1, Which Regulates VEGF Splicing
(A) SRSF1 is absent from the cytoplasm when WT1 is mutated. Immunofluorescence staining of SRSF1 (red) of normal, DDS (R366C), and WT1-rescued DDS
[DDS+WT1(+/)] podocytes. Nuclei are counterstained blue. Scale bar = 10 mm.
(B) SRSF1 is more nuclearly localized in DDS than in normal podocytes. Protein was extracted from whole cells or from nuclear extracts of podocytes and
subjected to immunoblotting for SRSF1.
(C) Nuclear SRSF1 is phosphorylated. Protein was extracted from flasks of DDS podocytes as either a cytoplasmic or a nuclear extract, and half-treated with
phosphatase and subjected to high-resolution SDS PAGE and immunoblotting using mouse monoclonal (maSRSF1) or goat polyclonal (gaSRSF1) antibodies to
SRSF1, the cytoplasmic protein laminin, and the nuclear protein lamin.
(D) SRSF1 is hyperphosphorylated in DDS. Protein was extracted from podocytes, immunoprecipitated with an SRSF1 antibody, and immunoblotted with
a pan-phospho SR antibody (top) or SRSF1 antibody (bottom).
(E) Protein was extracted from podocytes and half-immunoprecipitated with an anti-phosphoSR protein antibody. Both the IP and the crude protein extract were
immunoblotted with an SRSF1 antibody and actin as a loading control.
(F) Nuclear localization of SRSF1 inhibits distal splicing. Normal podocytes were transfected with a vector encoding SRSF1 that fails to shuttle into the cytoplasm
(nucleus-specific), and RNA was extracted and amplified for VEGF expression.
(G) Additional SRSF1 targets are alternatively spliced in DDS podocytes. RNA from normal or DDS podocytes was subjected to RT-PCR using exon spanning
primers for the MNK2 cDNA (top) or hnRNPA2/B1 (middle) or GAPDH (bottom).
(H) Knockdown of SRSF1-induced VEGF165b expression in DDS podocytes. DDS podocytes were transfected with scrambled siRNA (scr) or three different
siRNAs to SRSF1 in the 30UTR (siRNA1), in exons 2–3 (siRNA2) or exon 3 (siRNA3). See also Figure S2.
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Figure 3. Increased SRPK1 Expression Increases SRSF1 Nuclear Localization and VEGF Proximal Splicing
(A) SRPK1 is upregulated in DDS podocytes. mRNA was extracted from normal, DDS, or rescued podocytes and subjected to qPCR using primers specific for
SRPK1.
(B) SRPK1 protein is upregulated in DDS podocytes. Immunoblot (IB) using SRPK1 antibody in protein extracted from DDS podocytes, normal podocytes, and
wild-type WT1(+/) overexpressing podocytes.
(C) SRSF1 localization is SRPK1 dependent. Immunofluorescence for SRSF1 (red) is shown. DDS cells were treated with 10 mM of the SRPK1 inhibitor
SRPIN340 or by knockdown of SRPK1 in DDS podocytes. Scale bar = 10mm.
(D) SRPK1 inhibition switches splicing to VEGF165b. RT-PCR of mRNA extracted from normal or DDS podocytes untreated or treated with the SRPK1 inhibitor
SRPIN340 using primers for VEGF165 (top band) or VEGF165b (lower band).
(E) Knockdown of SRPK1 switches VEGF splicing. RT-PCR of RNA extracted from DDS podocytes transfected with three different siRNAs to SRPK1, or
scrambled siRNA (scr). VEGF165b or VEGF165 cDNA is used as a positive control.
(F) SRPK1 inhibition is antiangiogenic. Normal or DDS cells were suspended in matrigel with or without SRPIN340 and implanted into nude mice. Matrigel was
excised and photographed. The intensity of red haemoglobin was measured.
(G) RNA was extracted from the matrigel plugs and endothelial content was estimated from VEGFR2 expression level assessed by qRT-PCR. Bar charts are
mean ± SEM. See also Figure S3.
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WT1 Regulates VEGF Splicing by SRPK1 SuppressionVEGF165b isoform expression. Treatment of DDS podocytes
with SRPIN340 resulted in splicing to the distal splice site
(VEGF165b expression). SRPIN340 exerts 80% inhibition of
SRPK2 at 10 mM, but inhibits only one other of 140 serine threo-
nine kinases at that dose by more than 50% (ALK, 71%) (Fuku-
hara et al., 2006). To confirm that the switch in splicing was
due to an effect on SRPK1, three different siRNAs specific for
SRPK1 were used. qPCR showed that these inhibited SRPK1
expression to 35 ± 6, 34 ± 11, and 31 ± 16% of scrambled siRNA
for siRNA 9, 10, and 11, respectively. This was confirmed by
western blotting (Figure S3B). This compares with 20.5%
SRPK1 mRNA expression in the WT1 transfected DDS podo-
cytes. Figure 3E shows that all three siRNAs resulted in
VEGF165b expression in the DDS podocytes. To ensure that
the siRNAs were not acting through off-target effects, an
SRPK1 construct was generated that was insensitive to siRNA9.
Transfection of this into the siRNA9 transfected cells restored
DDS VEGF expression, inhibiting VEGF165b and favoring prox-
imal splicing (Figure S3C). qPCR of SRPK2, a related splice-
factor kinase, showed no change in DDS cells compared
with normal podocytes and was not affected by SRPK1 knock-
down. To determine whether the SRPK1 inhibition resulted in
a functional alteration of VEGF production, podocytes were
used in a matrigel angiogenesis assay (Figure 3F). When
implanted into nude mice, normal podocytes induced little
angiogenesis, as seen by mostly clear matrigel plugs. In contrast
DDS cells resulted in vascularized plugs (Figure 3F, lower).
In contrast, when DDS cells were treated with SRPIN340,
the vascularization was inhibited. To quantify vascularization,
qPCR for mouse VEGFR2 was carried out and quantitated
relative to a standard curve (Figure S3D). Figure 3G shows that
DDS podocytes induced more endothelialization of the plugs
than did normal podocytes and that this was reversed by
SRPIN340 treatment.
WT1 Binds the SRPK1 Promoter
To identify whether WT1 interacted directly with the SRPK1
promoter, we used chromatin immunoprecipitation (ChIP) to
determine whether WT1 could bind to the promoter region of
the SRPK1 gene. Figure 4A shows a diagram of the SRPK1
gene and a putative WT1 binding site (similar to the GC-rich
EGR consensus) close to the putative transcription start site.
Podocytes were subjected to nuclear extraction of the chro-
matin/protein complex, followed by shearing of the DNA with
sonication to generate fragments 200–1000 bp long. This was
then subjected to immunoprecipitation with an anti-WT1 anti-
body, and the precipitate was subjected to PCR using primers
across the transcriptional start. In LNCaP prostate cancer cells
overexpressing WT1, binding of WT1 to the VEGF promoter
has been seen in vitro (Graham et al., 2006). To determine
whether, in podocytes, WT1 also bound the VEGF promoter,
the precipitate was subjected to amplification of the VEGF
promoter in the same region. Primers to the GAPDH promoter
were used as a negative control. As a positive control, chromatin
was immunoprecipitated with an antibody to RNA polymerase II.
Figure 4B shows that the SRPK1 promoter sequence around the
transcriptional start site was precipitated with WT1 in normal
podocytes and rescued podocytes, but not in DDS podocytes.
In contrast, WT1 did not bind either the VEGF or the GAPDH774 Cancer Cell 20, 768–780, December 13, 2011 ª2011 Elsevier Incpromoters in either DDS or normal podocytes. To determine
whether the putative WT1 binding site was functional in the
SRPK1 promoter, a 1661-bp genomic fragment containing the
proposed transcriptional start site was cloned into a Lucif-
erase/Renilla reporter gene. The Renilla is under control of the
hTK promoter and acts as an expression control. The open
bars in Figure 4C show that the ratio of Luciferase to Renilla
was almost four times greater in DDS podocytes than in normal
podocytes, but this ratio was reduced in the rescued DDS podo-
cytes. Figure S4A shows that luciferase expression was
increased in all three DDS cell lines, R336C, M342R, and
G349C, compared with normal podocytes. To identify whether
the site of repression was located at the 10-bp WT1-binding
consensus sequence, this sequence was mutated (Figure 4C).
This increased luciferase expression in the normal and rescued
podocytes, but it did not significantly affect expression in any
of the DDS podocyte types (Figure 4C; Figure S4A), as the
mutant WT1 protein in these cells is unable to repress SRPK1
expression. However, there was a trend in the three DDS cell
lines toward reduced expression in the mutated reporters
compared to the wild-type. Therefore, to exclude the possibility
of other transcription-factor binding sites affecting expression,
a shorter (484-bp) sequence was used (Figure S4B). Again,
DDS cells had a higher luciferase expression than did normal
and rescued cells, and when the WT1 binding site was mutated,
luciferase expression in normal and rescued cells was again
increased, although not to the levels seen in DDS cells (Fig-
ure S4C). We therefore cannot rule out the possibility that addi-
tional regulators in the promoter region interact with the mutated
DDS protein, but it is clear that the mutant WT1 protein results in
elevated SRPK1 expression, at least in part through lack of
binding to the WT1 consensus binding sequence. To determine
whether the SRPK1 promoter was inhibited by exogenous WT1,
HeLa cells were transfected with the luciferase reporter gene
with or without wild-typeWT1. Figure 4D shows that transfection
of HeLa cells with wild-type WT1 resulted in a significant inhibi-
tion of luciferase expression to 30% of that in cells not trans-
fected with WT1. Figure 4E shows that this repression of the
normal SRPK1 promoter by wild-type WT1 to 31 ± 6% was
significantly lifted by the use of the WT1 binding site mutant
SRPK1 promoter (WTBSmut, 63 ± 6%), but again not to 100%,
so additional regulators may be active.
SRPK1 Is Upregulated and SRSF1 Is Localized to Nuclei
in Human DDS
To determine whether the upregulation of SRPK1 was also seen
in humanDDS patients in vivo, RNAwas extracted from paraffin-
embedded sections of renal cortex from five patients with Denys
Drash Syndrome or five histologically normal kidney sections.
Figure 4F shows that SRPK1 was significantly greater (4.3 ±
1.2-fold, p < 0.01, one sample t test) relative to GAPDH in the
DDS patients. To determine whether SRSF1 was relocated
from the cytoplasm, sections were stained with SRSF1 antibody.
Although there was no difference in tubular staining of SRSF1
between normal and DDS patients, in the glomeruli in the normal
kidneys there was substantial podocyte cytoplasmic staining
(Figure 4G, left, arrows), whereas in the glomeruli of DDS
patients, staining appeared to be more localized to the nuclei
of the podocytes (Figure 4G, right, arrows)..
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Figure 4. WT1 Represses SRPK1 Expression by Binding the SRPK1 Promoter Region
(A) SRPK1 gene structure. Black, promoter region; gray, WT1 binding site; silver, 50UTR; white, coding sequence of exon 1. Arrows indicate primer locations.
Numbers are bp relative to the start codon.
(B) WT1 binds the SRPK1 promoter. Nuclear extracts from podocytes were sheared to fragment DNA, immunoprecipitated with polymerase II antibody, human
IgG, or a WT1 antibody, and subjected to PCR using primers to detect the region around the SRPK1 transcriptional start site (TSS) or the VEGF or GAPDH
promoters.
(C) DDSmutations relieve SRPK1 repression. Podocytes were transfected with an SRPK1 promoter-luciferase reporter vector (white bars), or the same promoter
with a 10-bp mutation of the WT1 consensus sequence (WT1CSmut; black bars).
(D)WT1 represses SRPK1 expression. HeLa cells were transfected with the wild-type promoter reporter gene alone (open bars) or also withWT1 (silver bars), and
bioluminescence was measured.
(E) The 10-bp consensus sequence adjacent to the TSS is responsible for part of the repression. HeLa cells transfected with WT1 and the wild-type SRPK1
promoter (silver bars) or WT1 and the mutated SRPK1 promoter (black bars). Luciferase/Renilla is expressed as a percentage of bioluminescence in the absence
of WT1 (white bar in D).
(F) qPCR of SRPK1 RNA from histologically normal kidney (n = 5) or children with DDS (n = 5, p < 0.05). Bar charts are mean ± SEM.
(G) Immunohistochemistry for SRSF1 of kidney biopsies of DDS subjects (right) compared with normal subjects (left). Podocytes are shown by arrows.
Scale bar = 15 mm. See also Figure S4.
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WT1 Regulates VEGF Splicing by SRPK1 SuppressionSRPK1 Inhibition Inhibits Angiogenesis
To determine whether the proangiogenic VEGF isoform expres-
sion due to SRPK1 is necessary for angiogenesis, we employed
a widely used model of choroidal neovascularization that is
amenable to local administration of pharmacological tools.
Treatment of epithelial cells with 10 mM SRPIN340 resulted in
an increase in VEGF165b expression (Nowak et al., 2010). In
a mouse model of choroidal neovascularization 3 days after
treatment with SRPIN340 (10 pmol/eye), the ratio of total VEGF
(containing exon 2/3) to proangiogenic isoforms (containing
exon 8a) was significantly greater than in saline-treated controls
(Figure 5A), as determined by qPCR. Two weeks after SRPIN340
treatment, there was a substantial and significant inhibition of
fluorescein leakage (Figure 5B) and lesion size (Figure 5C) in
the SRPIN340-treated mice compared with both controls and
mice treated with eye injection with an inhibitor of a closely
related kinase, Clk1/4 (TG003). The inhibition of angiogenesis
was similar to that seen with recombinant VEGF165b protein
(Hua et al., 2010). To determine whether the inhibition of splicing
to VEGF165 was sufficient to inhibit tumor growth and angiogen-
esis, LS174t colorectal tumor cells, the growth of which has
previously been shown to be inhibited by the antiangiogenic
actions of VEGF165b, were stably transfected with an SRPK1-
shRNAi lentiviral vector. Stable cell lines (Figure S5A) were
generated and SRPK1 levels were measured by qPCR. These
were knocked down by 96% (Figure S5B). SRPK1 knockdown
cells grew at the same rate as the scrambled shRNAi cells. To
determine whether SRPK1 knockdown affected VEGF splicing,
RNA and protein were extracted and subjected to RT-PCR and
ELISA, respectively. SRPK1 shRNAi-expressing cells showed
stronger expression of VEGF165b mRNA (Figure 5D) and
VEGF165b protein in the cell (Figure S5C) and the media (Fig-
ure S5D). To determine whether the SRPK1 knockdown resulted
in a functional alteration of VEGF, cells were transfected with
SRPK1 shRNAi lentivirus, and media collected for in vitro angio-
genesis assays. Media from untransfected cells stimulated
endothelial cell tube formation on fibroblasts, but media from
SRPK1 shRNAi-transfected cells had no effect (Figure 5E).
These tumor cells were then implanted into nude mice and the
tumor growth rate was measured. The SRPK1 shRNAi cells
formed smaller tumors than did the scrambled shRNAi controls,
and the tumors grew more slowly (Figure 5F). Staining of these
cells for microvascular density by VEGFR2 immunofluorescence
showed significantly lower density for SRPK1 shRNAi cells than
for scrambled controls (Figure 5G).
DISCUSSION
These results indicate a link between the physiological role of an
important tumor suppressor gene (WT1) and regulation of the
angiogenic or antiangiogenic properties of VEGF and other
genes by alternative splicing. There have been many studies
identifying alternative splicing as a process that regulates onco-
genesis. For instance, a splice variant of p53 (p47) is an N-termi-
nally deleted form of p53 and inhibits its tumor suppressor
activity (Ghosh et al., 2004), and a correlation was seen between
inactive p53 isoforms and VEGF165b splicing in colorectal
cancers (Dı´az et al., 2008). However, in this case as in many
others, it is the tumor suppressor gene itself that is alternatively776 Cancer Cell 20, 768–780, December 13, 2011 ª2011 Elsevier Incspliced to give different isoforms. It is less common to find a link
between a tumor suppressor gene and a tumor regulatory
process that involves alternative splice-site regulation. One
such example is the regulation of alternative Fas splicing by
RBM5, whereby RBM5 binds to U2AF65 and prevents inclusion
of exon 6 of Fas. Thus, the tumor suppressor gene acts by
directly interacting with the spliceosome (Bonnal et al., 2008).
Other tumor-mediated pathways have also been implicated;
for instance, Ras increases alternative splicing of KLF6, a
tumor suppressor gene in colorectal cancer, through PI3K and
Akt, and through a mechanism that is also SRSF1 mediated,
suggesting that Akt-mediated phosphorylation of SRSF1 is
also sufficient to alter splicing of the tumor suppressor gene
itself (Yea et al., 2008). The data presented here go one
step further and demonstrate the mechanism by which a muta-
tion in a known tumor suppressor gene causes a change in
a splicing process that results in alternative splicing of other
genes that contribute to tumor progression (in this case by
angiogenesis). As WT1 is implicated in renal disease, gonadal
development, and in several cancers, the mechanistic link
between WT1 expression (including WT1 splice variants),
SRPK1 expression, and SRSF1 activity will be of significant
interest. It had previously been shown that WT1 could modify
splicing and interact directly with splicing proteins, for instance
by binding U2AF65, but this interaction required the KTS
sequence (Davies et al., 1998). The finding that only the
isoforms lacking the KTS domain (and hence non-RNA binding)
repress SRPK1 expression provides another mechanism
through which WT1 can alter RNA processing: transcriptional
repression of a splicing-factor kinase. Thus, one of the conse-
quences of misexpression of WT1 in tumors is an altered pattern
of alternative splicing of key cancer-associated genes (including
VEGF), not only through direct interaction with splicing factors
(Davies et al., 1999), but also through controlled expression of
splice-factor kinases.
The upregulation of SRPK1 expression by WT1 mutants (and
hence suppression of SRPK1 by wild-type WT1) indicates that
SRPK1 upregulation may be a common cancer-related event.
It has been shown that SRPK1 is upregulated in pancreatic,
breast, and colon carcinomas (Hayes et al., 2007), but is reduced
in neuroblastoma (and this correlates with drug resistance)
(Krishnakumar et al., 2008). This is consistent with studies
showing that in tumor cells, the target for SRPK1, SRSF1, is
phosphorylated and located in the nucleus (Sanford et al.,
2005), as seen in this study in HeLa cells but not in HEK293T cells
(an epithelial cell line that is not tumorigenic). Thus, nuclear
SRSF1 may be more common in cultured cancer cells than in
differentiated cells, a hypothesis that needs to be tested. It indi-
cates that phosphorylated, nuclear SRSF1 is indicative of an
angiogenic phenotype in that it results in proximal splicing and
production of angiogenic VEGF isoforms. This is supported by
work showing that IGF-mediated PKC activation induces binding
of phosphorylated SRSF1 to the VEGF pre-mRNA (Nowak et al.,
2010). However, this is evidence that upregulation of SRPK1 is
by a specific mechanism. It also identifies a link between WT1
and a putative mechanism for the glomerular dysfunction of
DDS, proposed by Schumacher et al. to be mediated by alterna-
tive VEGF splicing (Schumacher et al., 2007), and for which there
is indirect evidence from overexpression of WT1 mutants in.
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Figure 5. SRPK1 Inhibition is Antiangiogenic
(A) Mice underwent laser photocoagulation and were treated with SRPIN340 (inhibits SRPK1, n = 24), TG003 (inhibits Clk1/4, n = 18), or vehicle (n = 24).
Two to three days later, six HBSS-treated and six SRPIN340-treated mice were killed, their eyes were enucleated, and their RNA was extracted and subjected to
qRT-PCR for total VEGF (primers in exon 3) or exon-8a-containing VEGF (e.g., VEGF164).
(B) The remainingmice were treated again 7 days later with the compounds and then, after another 7 days, subjected to fluorescein angiography. Lesion size was
scored blind. Scale bar = 300 mm.
(C) The mice were then killed and their retinal membranes flat-mounted and stained for lectin to identify choroidal angiogenesis (red). The size of the lesions was
measured. **p < 0.01, *p < 0.05 compared with PBS, ANOVA. Scale bar = 100 mm.
(D) LS174t colon cancer cells were infected with lentivirus containing SRPK1-shRNAi or scrambled siRNA (ctrl) and selected with puromycin. Stable cell lines
were subjected to RT-PCR for VEGF165b and VEGF165 levels.
(E) Knockdown of SRPK1 reduces the angiogenic potential of media. Cells were infected with SRPK1 shRNAi and the media collected. Media was used in an
in vitro coculture assay of endothelial cells and fibroblasts, and cells stained for CD31 (red, endothelial) and Hoechst (nuclei). Spread of endothelial cells was
determined by measuring the ratio of area covered by CD31 staining relative to that covered by Hoechst staining. **p < 0.01. Scale bar = 200 mm.
(F) Tumor cells were implanted into nude mice and tumors allowed to grow for 12 days. Tumors are outlined in black. Tumour diameters were measured by
callipers. ***p < 0.001 by two way ANOVA.
(G) Tumors were excised and stained for VEGFR2 (red) and Hoechst (blue) and vessel density was determined by VEGFR2 staining relative to Hoechst. *p < 0.05
compared with scrambled siRNA, t test. Scale bar = 20 mm. Bar charts are mean ± SEM. See also Figure S5.
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are postulated to be caused by altered VEGF function (Natoli
et al., 2002).CanWe recently showed that neonatal retinal neovascularization
induced by hyperoxia is reduced by SRPIN340 treatment
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WT1 Regulates VEGF Splicing by SRPK1 Suppressionshowing that SRPK1 inhibition is effective in tumor models of
cancers that are treated by anti-VEGF therapy. The substantial
inhibition of angiogenesis coupled with reduced lesion size
demonstrates that interfering with VEGF splicing mechanisms
is a rational target for antiangiogenic therapy in tumors. In partic-
ular, it suggests that angiogenesis may be driven in tumors that
lack functional WT1 (exemplified by LS174t cells), or have
enhanced SRPK1 expression (Koesters et al., 2004), by control
of VEGF splicing rather than (or as well as) control of VEGF
expression. This has implications for the rational use of anti-
VEGF agents, as VEGF inhibitors have been shown to be amelio-
rated in the presence of increased VEGF165b expression (Varey
et al., 2008).
These results provide a potential mechanism for a different
antiangiogenic therapeutic approach (specifically, the inhibition
of SRPK1), and they also identify SRSF1 localization as a
possible rational diagnostic marker for WT1 dysfunction in the
context of angiogenesis. Alternative splicing of several other
cancer-associated genes may also be affected through WT1’s
ability to regulate SRPK1.
EXPERIMENTAL PROCEDURES
Human Samples and Ethics
All human samples were anonymized and experiments were approved by the
North Bristol Ethics Committee (Southmead Hostpital) number 07/H0102/45.
Cell Culture and Transfection
Specific details of the experimental procedures are given in the online
supplement.
The conditionally immortalized podocytes used were from a healthy indi-
vidual and from three patients suffering from Denys Drash Syndrome
(R336C, M342R, and G349C). After growing to the required confluence, the
podocytes were thermoswitched at 37C for 14 days to ensure growth arrest
and differentiation. Both podocyte cell types (DDS and normal) were used at
the same stage of differentiation (14 days thermoswitched).
Protein Studies: Immunoblotting and Immunoprecipitation
Both whole-cell lysate (nuclear and cytoplasmic) protein extraction and
nuclear protein extracts were used as described in the online supplement.
The extracts were then immunoblotted using either mouse anti-SRPK1 (anti-
SRPK1; BD 611072; 1:1000), rabbit anti-panVEGF (Santa Cruz A20 sc-152;
1:500), mouse anti-VEGFxxxb (MAB3045; R&D; 1:500), goat anti-SRSF1
(SC10255; 1:500), mouse anti-SRSF1 (AK96) (Santa Cruz SC-33562), or rabbit
anti-GAPDH (Sigma G9545, 1:2000). For immunoprecipitation phospho-
SRSF1 studies, cell lysates were incubated with mouse anti-SRSF1 (Santa
Cruz SC-33562) or anti-Pan-phospho-SR antibody (Santa Cruz SC-13509)
and Protein G Dynabeads (Invitrogen). To detect phosphorylated SRSF1, the
eluent was immunoblotted with either anti-SRSF1 or the anti-Pan-phospho-
SR antibody (1:500).
ELISA
A pan-VEGF capture antibody (Duoset VEGF ELISA DY-293; R&D Systems)
and recombinant human VEGF165 or VEGF165b standards were used. Bio-
tinylated goat anti-human VEGF (0.025 mg/ml; R&D Systems) or mouse anti-
human VEGF165b (clone 264610/1, 0.025 mg/ml, R&D Systems) were used
as detection antibodies. Details are given in the online supplement.
Semiquantitative PCR and qPCR
mRNA was extracted from differentiated podocytes using standard method-
ology, given in the online supplement. To extract RNA from paraffin-
embedded DDS kidneys (n = 5) and paraffin-embedded non-WT1 child
kidneys (n = 5), two sections of 6 mm thickness were used from each. RNA
was then extracted using RNeasy FFPE kit (QIAGEN). RT-PCR was performed778 Cancer Cell 20, 768–780, December 13, 2011 ª2011 Elsevier Incto differentiate between exon-8a- and exon-8b-containing isoforms within the
same sample in the same reaction using primers specific to exon 7a and the 30
untranslated region of the VEGF gene (Nowak et al., 2008). For qPCR, 1% of
the cDNA from the cell lines was used per reaction, whereas 5% of the
cDNA from paraffin-embedded sections was used. The qPCR reaction was
set up using Roche SyBr Green and run in an ABI 7000. Validated primers
specific to SRPK1, SRSF1, and GAPDH were used for the qPCR.
Chromatin Immunoprecipitation
ChIP was performed on the differentiated podocytes using the Imprint ChIP Kit
(Sigma). Cells were incubated with 1% formaldehyde to crosslink DNA to
protein. The cells were then lysed and DNA sheared to about 1000 bp using
a sonicator. The DNA-protein mixture, incubated with WT1, polymerase II
antibody, or nonspecific IgG, was immunoprecipitated, and the crosslinked
DNA-WT1 complex was released using proteinase K, after which the DNA
was cleaned up and eluted using GeneElute Binding Column (Sigma) and
the eluted DNA was subjected to PCR to detect SRPK1, VEGF, and GAPDH
promoter regions.
Luciferase Assays
A 1661-bp fragment and a 484-bp fragment containing the upstream promoter
sequence of SRPK1 were amplified from genomic DNA and cloned into pGL3,
as described in the online supplement, to generate the wild-type SRPK1
promoter. The SRPK1 promoter sequence was verified by restriction analysis
and sequencing. The putative WT1 binding site located 119 bp to 110 bp
upstream of the SRPK1 start codon was mutated from GGGGCGGGGG to
GAATTCAAAA as described in the online supplement.
Animal Experiments
All animal experiments were approved by the University of Southern California
(USC) Animal Use Committee (ocular experiments), or under license by the UK
Home Office and in accordance with the University of Bristol ethical review
panel (tumor experiments).
Induction of Choroidal Neovascularization
Details are given in the online supplement. C56Bl/6J mice were anesthetized
by intraperitoneal injection of ketamine and xylazine hydrochloride. Four
photocoagulation lesions were delivered with a diode green laser between
the retinal vessels 1–2 disc diameters apart in each eye. Two ml of saline,
10 ng rhVEGF-A165b, 100 pmol SRPIN340, or 100 pmol TG003 was injected
into the vitreous immediately after photocoagulation and 7 days later. Fourteen
days after laser treatment, fluorescein angiography of the fundi was carried
out, and the animals were sacrificed after imaging. Eyes were enucleated
and fixed. Three animals given SRPIN340 or saline were sacrificed 3 days after
photocoagulation, and RNA was extracted for qPCR.
Tumor Studies
LS174t colorectal tumor cells were infected with lentiviral SRPK1 shRNAi or
standard and selected with puromycin. Cells were checked for positive
expression by GFP (Figure S5A). SRPK1 knockdown was assessed by
qPCR as above. VEGF was assessed as above using a VEGF165b-specific
ELISA (see Methods in the Supplemental Information), and a pan VEGF ELISA.
The difference was used to calculate VEGF165.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2011.10.016.
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